PARSPORT
Disease site: Head and Neck
Treatment Modality: Radiotherapy
Status: In active follow-up
The PARSPORT trial is designed to demonstrate a difference in the proportion of patients suffering xerostomia (dry mouth) of grade 2 or more, 1 year after treatment, in head and neck cancer patients treated with parotid-sparing intensity modulated radiotherapy or conventional radiotherapy.
94 patients were recruited from January 2003 to December 2007 from 6 UK centres.
The work is supported by the NCRI CTrad Group and the NCRI Head and Neck Cancer Studies Group.
Chief Investigator: | Dr Chris Nutting |
Sponsor: | The Royal Marsden NHS Foundation Trust |
Source of funding: | Cancer Research UK |
ISRCTN: | 48243537 |
In the Clinical Trials Section
